ODM-207 – First-in-human Phase 1 study of BET inhibitor for solid tumour patients
RUCHITA KARMAKAR, AMITY UNIVERSITY KOLKATA BET (Bromodomain and extra terminal domain) proteins are described to be epigenetic and anti-cancer drug targets. This was the first-in-human study that judged the pharmacokinetics and prior activity of ODM-20, the inhibitor of BET in patients having solid tumours. The main objective was to determine the tolerability, dose-limiting toxicities (DLT), […]